Positive results announced for metastatic tumour treatment
A new anti-tumour treatment for metastatic solid tumours has achieved encouraging results in a Phase I clinical trial. DT-9081, developed by biopharmaceutical company Kainova Therapeutics, is a proprietary, oral small molecule EP4 receptor (EP4R) antagonist in patients with advanced, recurrent, and metastatic solid tumours. According to Kainova, the… Read More